Abstract: Provided is a position information providing system which can reduce a time required for acquiring position information. An indoor transmitter is adapted to provide position information by using a second positioning signal compatible with a first positioning signal which is a spread spectrum signal from each of a plurality of satellites. The indoor transmitter includes an EEPROM which stores therein position data for identifying an installation location thereof, an FPGA operable to generate a second positioning signal including the position data as a spread spectrum signal, and a transmitting section operable to transmit the spread spectrum signal. The second positioning signal is generated to repeat the same content in a cycle shorter than that of the first positioning signal.

Abstract: A gene encoding a production amount-potentiating factor is introduced into an animal cell to transform the cell. Alternatively, a protein production gene and the gene encoding the production amount-potentiating factor are introduced into the animal cell to transform the cell. Herein, as the production amount potentiating factor, there is used a factor having caspase activity inhibiting activity and/or protein biosynthesis activity potentiating action, for example, baculovirus P35. Further, the animal cell is cultured by a culturing method under a condition that apoptosis is not induced, so that a protein is mass-produced.

Abstract: A modified transposon vector and a method for introducing a foreign gene into a cell are provided.

Abstract: An amplifying device includes an amplifier including a first amplifying element with a drain voltage thereof being controlled, and a second amplifying element, the amplifier amplifying a transmission signal with the first and second amplifying elements, synthesizing the transmission signals amplified by the first and second amplifying elements, and outputting the synthesized transmission signal; a distortion compensator part which performs distortion compensation on the input signal in accordance with a compensation coefficient derived from a difference between a input signal and a feedback signal generated from a portion of a signal output from the amplifier; and a controller part which controls the drain voltage of the first amplifying element in response to a result of a comparison between a power level of the input signal prior to the distortion compensation operation by the distortion compensator part and a threshold value.

Abstract: The amplifying apparatus includes an amplifier having a circuit constant determined so as to satisfy a condition for E-class operation; power detecting unit which detects an output electricity from the amplifier; and controlling unit which controls the circuit constant in accordance with the output power detected by the power detecting unit.

Abstract: The disclosed image forming apparatus includes a rotatable image holding body configured to hold an electrostatic latent image on a surface of the image holding body, a developing device including a forward rotation developing roller rotatable in a same rotational direction as that of the rotatable image holding body and a reverse rotation developing roller rotatable in a reverse rotational direction to that of the rotatable image holding body, which supply a two-component developer to the surface of the image holding body to form a toner image corresponding to the electrostatic latent image, and a control unit configured to control rotation of the image holding body, the forward rotation developing roller, and the reverse rotation developing roller to supply the two-component developer. The control unit controls the rotation of the image holding body to start after a predetermined time period from starting the rotation of the forward rotation developing roller and the reverse rotation developing roller.

Abstract: When genes encoding three kinds of proteins constituting fibrinogen, an ? chain (or variant of ? chain), a ? chain and a ? chain (or variant of ? chain) are incorporated into an animal cell, a constitutional ratio of respective genes is such that a ? chain (and/or variant of ? chain) gene is an equal amount to a 1000-fold amount relative to an ? chain (and/or variant of ? chain) gene and a ? chain gene and, further, by using a baculovirus P35 gene, a recombinant fibrinogen highly producing cell is prepared.

Abstract: A novel medicament for treating neurodegenerative diseases, especially for ameliorating dyskinesia, comprising as an active ingredient selenoprotein P and/or a peptide fragment or a series of peptide fragments derived from said protein is provided. The novel medicament for treating neurodegenerative diseases, especially for ameliorating dyskinesia, according to the present invention is suitably applicable to diseases with decrease in motor function.

Abstract: An asparagine-linked disialoundecaoligosaccharide-fatty acid amide, a drug containing the same, and a drug containing an asparagine-linked disialoundecaoligosaccharide.

Abstract: The amplifying apparatus includes an amplifier having a circuit constant determined so as to satisfy a condition for E-class operation; power detecting unit which detects an output electricity from the amplifier; and controlling unit which controls the circuit constant in accordance with the output power detected by the power detecting unit.

Abstract: The present invention provides a peptide fragment or a series of peptide fragments having a cell death-inhibitory activity, having the amino acid sequence consisting of 103 amino acid residues at the C-terminal of selenoprotein P, or having said amino acid sequence with one or several amino acid residues therein being deleted, substituted or added, or having a partial sequence of either of the above amino acid sequences, a medicament for treatment comprising said peptide fragment or a series of peptide fragments, an antibody to said peptide fragment or a series of peptide fragments, and a method for screening a cell death-inhibitory activity using said peptide fragment or a series of peptide fragments. The preferable peptide fragment or a series of peptide fragments of the present invention has the amino acid sequences shown in SEQ ID NO: 1 and/or SEQ ID NO: 2 or has a partial sequence thereof.

Abstract: An amplification apparatus including a plurality of amplifiers includes a carrier amplifier, a peak amplifier including a gate bias circuit including a resistor for supplying a gate bias voltage, a comparator for outputting a resultant signal determined by comparison of a predetermined threshold voltage with a voltage across the resistor included within the gate bias circuit, and a failure detecting circuit for detecting whether a failure in the plurality of amplifiers is caused or not based on the resultant signal.

Abstract: It is intended to provide an antibody showing immunoreactivity selectively to ADAMTS-13 and applications of this antibody in epitope analysis or diagnosis of an ADAMTS-13 autoantibody-positive patient. Alternatively, it is intended to provide a process for producing and use of a modified ADAMTS-13 molecule partially deleted aiming at the application in pharmaceutical products. An antibody specific for ADAMTS-13 which can be obtained from a warm-blooded animal immunized and sensitized with a polypeptide containing a part or the whole of ADAMTS-13 amino acid sequence; a process for producing an antibody comprising a step of immunizing and sensitizing a warm-blooded animal with a polypeptide containing a part or the whole of ADAMTS-13 amino acid sequence; use of the above-described antibody including a method of detecting and purifying ADAMTS-13; and a modified ADAMTS-13 molecule partially deleted are provided.

Abstract: A blood-viscosity reducing agent contains a protein derived from Bacillus subtilis natto and including, sequentially from an amino group terminal, a first structural amino acid sequence having alanine, threonine, aspartic acid, glycine, valine, glutamic acid, tryptophan, asparagine, valine, aspartic acid, glutamine, isoleucine, aspartic acid, alanine, proline, lysine, alanine, tryptophan, alanine, leucine, glycine, tyrosine aspartic, acid, glycine, threonine, glycine, threonine, valine, valine, alanine, serine, isoleucine, aspartic acid, threonine, glycine, valine, glutamic acid, tryptophan, asparagine, histidine, proline, alanine, leucine, lysine, glutamic acid, lysine, tyrosine, arginine, glycine, tyrosine, asparagine, proline, glutamic acid, asparagine, proline, asparagine, glutamic acid, proline, glutamic acid, asparagine, glutamic acid, methionine, asparagine, tryptophan, tyrosine, aspartic acid, alanine, valine, alanine, glycine, glutamic acid, alanine, serine, proline, tyrosine, aspartic acid, aspartic

Abstract: The present invention is a bacteriolytic agent containing a cationic surfactant (A) of which a counteranion is an acid having a pKa (25° C.) of 0 to 10. As the counterion, a carboxylate anion is preferable. As the cationic surfactant (A), a quaternary ammonium salt-type surfactant is preferable. Examples of the useful substance include a protein, an amino acid, a nucleic acid, an antibiotic, sugars or vitamins. The bacteriolytic agent of the present invention is excellent in a bacteriolytic power in a step of extracting a useful substance from a microorganism (useful substance producing bacterium etc.). In addition, denaturation of the useful substance during the step is small.

Abstract: A gene encoding a production amount-potentiating factor is introduced into an animal cell to transform the cell. Alternatively, a protein production gene and the gene encoding the production amount-potentiating factor are introduced into the animal cell to transform the cell. Herein, as the production amount potentiating factor, there is used a factor having caspase activity inhibiting activity and/or protein biosynthesis activity potentiating action, for example, baculovirus P35. Further, the animal cell is cultured by a culturing method under a condition that apoptosis is not induced, so that a protein is mass-produced.

Abstract: A novel medicament for treating neurodegenerative diseases, especially for ameliorating dyskinesia, comprising as an active ingredient selenoprotein P and/or a peptide fragment or a series of peptide fragments derived from said protein is provided. The novel medicament for treating neurodegenerative diseases, especially for ameliorating dyskinesia, according to the present invention is suitably applicable to diseases with decrease in motor function.

Abstract: To cancel a reflected wave reflected from a connecting portion (22) and leaking into a feedback signal when a non-matched component is connected, the reflected wave is extracted by a circulator (30) and its phase and amplitude are adjusted by a vector adjusting circuit (32), and then the thus adjusted reflected wave is vector-summed with the feedback signal in a vector sum circuit (34).

Abstract: The present invention provides an amplifier unit including a carrier amplifier biased for Class A or Class AB operation; a peak amplifier biased for Class B or Class C operation, wherein an input signal is input to the carrier amplifier and the peak amplifier, and wherein output signals from the carrier amplifier and the peak amplifier are synthesized to output therefrom; a comparator configured to compare a gate bias voltage of a transistor device in the peak amplifier with a predetermined threshold voltage and output a first output signal; and a failure detection circuit configured to output a second output signal indicating presence or absence of failure, based on the first output signal received from the comparator.

Abstract: This invention is intended to isolate and identify a vWF-specific cleaving protease. The vWF-specific cleaving protease cleaves a bond between residues Tyr 842 and Met 843 of vWF and comprises a polypeptide chain having Leu-Leu-Val-Ala-Val (SEQ ID NO: 1) as a partial sequence, and more preferably comprises a polypeptide chain having the partial N-terminal amino acid sequence of a mature protein, Ala-Ala-Gly-Gly-Ile-Leu-His-Leu-Glu-Leu-Leu-Val-Ala-Val (SEQ ID NO: 2), and having a molecular weight of 105 to 160 kDa in SDS-PAGE under reducing or non-reducing conditions. Isolation and identification of this vWF-specific cleaving protease have led to the possibility of replacement therapy for patients having diseases resulting from a deficiency of the protease, such as thrombotic thrombocytopenic purpura.